Clinical Trial Update: Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the radiotracer [18F]MPPF as a brain tracer for serotonin 5-HT1A receptors, with completed status in Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• [18F]MPPF

Snippet

Sponsor: Institute for Neurodegenerative Disorders | Conditions: Parkinson Disease | Phase 1 | Status: COMPLETED